Opendata, web and dolomites

VDJtargeting SIGNED

Engineering T cells and B cells for Immunotherapy using V(D)J recombination

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VDJtargeting project word cloud

Explore the words cloud of the VDJtargeting project. It provides you a very rough idea of what is the project "VDJtargeting" about.

   expressed    lack    facilitated    ex    utilizing    antigenic    efficacy    coding    adverse    rare    reliance    iuml    locus    subjected    sequences    allelic    secret    mice    auto    activating    immune    gene    flanked    antibody    scaling    oncogenic    car    differentiated    integrate    risk    adeno    rss    engineered    proliferation    safe    efficient    vivo    autoimmune    therapeutic    expressing    diseases    secreted    immunotherapy    region    ab    genetic    disease    exclusion    recombination    reducing    off    chimeric    switching    diminished    recognition    cancers    incorporate    spurious    implanted    vdj    clinical    cells    previously    reduces    memory    negative    endogenous    injected    maturation    expression    receptor    accompanied    date    chains    ve    engineer    cell    aav    class    potent    ameliorate    somatic    express    loci    manipulations    constant    retention    promoterless    antigen    signal    tcr    hypermutation    affinity    cancer    rag    engineering    na    promoter    haematological    lymphocytes    escape    integration    inducibly    autoimmunity    activation    mainly    vectors    shown    desired    models    inserted    genes   

Project "VDJtargeting" data sheet

The following table provides information about the project.

Coordinator
TEL AVIV UNIVERSITY 

Organization address
address: RAMAT AVIV
city: TEL AVIV
postcode: 69978
website: http://www.tau.ac.il/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 1˙496˙875 €
 EC max contribution 1˙496˙875 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TEL AVIV UNIVERSITY IL (TEL AVIV) coordinator 1˙496˙875.00

Map

 Project objective

T cell engineering has shown clinical success mainly in haematological cancers, but scaling up is challenging due to reliance on ex vivo manipulations. In addition, B cell engineering has not shown therapeutic efficacy to date. Here, we propose a novel immunotherapy approach, allowing safe and efficient engineering of B cells and T cells, both ex vivo and in vivo. We will use adeno associated vectors (AAV) to integrate chimeric antigen receptor (CAR) or T cell receptor (TCR) genes into loci coding TCR chains and to integrate antibody (Ab) genes into loci coding Ab chains. Previously, we used AAV facilitated gene targeting in vivo to ameliorate genetic diseases in mice. For lymphocytes we develop “VDJ targeting”: A promoterless receptor/Ab gene flanked by recognition signal sequences (RSS) will be inserted into the endogenous locus by the recombination activating gene (RAG) complex during V(D)J recombination. Only developing lymphocytes, expressing RAG, will incorporate the receptor/Ab gene, which will thus be expressed in potent naïve cells from the strong endogenous promoter. Targeted developing cells are subjected to negative selection, thus reducing risk of adverse autoimmunity. Lack of promoter reduces spurious expression and oncogenic risk upon rare off-target integration. Targeting endogenous loci may allow allelic exclusion. In B cells it may allow utilizing the endogenous constant region to express a B cell receptor and, upon activation, a secreted Ab. Activation may be accompanied by proliferation and affinity maturation, including somatic hypermutation and class switching, to allow a potent immune response, memory retention and diminished antigenic escape. Where controlled autoimmunity is desired, we will engineer B cells to inducibly secret an auto-Ab. We will demonstrate efficacy in cancer and autoimmune disease models implanted with lymphocytes that we engineered while ex vivo differentiated and in mice injected with vectors for in vivo VDJ targeting.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VDJTARGETING" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VDJTARGETING" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

MITOvTOXO (2020)

Understanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell

Read More